You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 359 Developing human placental CD34-derived natural killer cells with high affinity and cleavage resistant CD16 and secreted IL-15 (CYNK-201) for cancer immunotherapy

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
359 Developing human placental CD34-derived natural killer cells with high affinity and cleavage resistant CD16 and secreted IL-15 (CYNK-201) for cancer immunotherapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gergues M, Zhao Y, Raitman I, et al
359 Developing human placental CD34-derived natural killer cells with high affinity and cleavage resistant CD16 and secreted IL-15 (CYNK-201) for cancer immunotherapy
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0359